Autor : Peña, David1-2
1Internal Medicine Specialist
2 Pulmonology Specialist U.B.A.
Thecomparative study of associations of monteÂlukast-loratadine versus montelukast-desloratadiÂne
for the treatment
of persistent allergic rhinitis published in this issue showed
the non-inferiority of the second option
in relation to the comparator.
Itshould be noted that the
prevalence of persisÂtent allergic rhinitis in Mexico is high,
reaching up to 48% in some regions, so the sample size in this study is
not significant, a fact to take into
account for the conclusions.
Butconsidering that the advantages
of desloÂratadine over loratadine are not relevant, and that they also have
a similar profile of adverse and unÂwanted
effects, the combination of either of them with montelukast
allows for a similar outcome, just as it happened.
Althoughdesloratadine
is a more recently develÂoped molecule, with greater dose-related
potency of action (5 mg is equivalent to 10 mg of loratadine) and differences in its half-life, its effects on
persisÂtent allergic rhinitis are not significantly different, as most of those who
treat this condition have been able to confirm
from their clinical experience.
Furthermore, within
the arsenal of second-genÂeration
antihistamines, both in monotherapy and in combination, the choice of drugs
for a specific patient should be guided primarily by evaluating their
previous experience with such drugs
and their response to them,
which can be highly variÂable.
This suggests that regardless of the chosen molecule,
there is great individual variation in
response.
Therefore, when choosing an antihistamine
for the treatment
of persistent allergic rhinitis, whethÂer it is a first
or second-line drug, or combined
with montelukast, as in this case, or associated
with corticosteroids or decongestants, the same principle
applies. The patient’s previous response to the medication is the first
factor to consider. In the absence of such information, the choice of the antihistamine
should be based on the clinical
experience or preference of the treating physician.
A
second factor to take into account when
choosing an antihistamine is its cost, since
there can be considerable differences
between drugs, with more recently developed molecules typically being more expensive.
Therefore, it is reasonable to expect this cost
difference to be present in
the combination with montelukast, resulting in a more expensive prodÂuct overall.
Theeconomic factor will have greater
or lesser importance in each country depending on the
local prices of the products and the percentage of the price borne by patients, according to the health coverage
they have to access the drugs.
Clearly, the economic factor will be more relÂevant in cases where the patient does
not have health coverage for his/her
medication, so it would be a good practice to consider the cost of the
anÂtihistamine when making the choice.
Whileit is not common
to consider the factors mentioned in research studies, it would be advisÂable
when making a therapeutic decision to conÂsider statistically significant data and conclusions,
as well as the individual history of the patient, and the cost of different treatment alternatives in relation to their potential benefit.